Innovators on verge of winning California battle over biosimilar switches
This article was originally published in Scrip
Executive Summary
California is on the verge of adopting a law that would authorize pharmacists in the state to substitute an FDA-approved biosimilar medicine for an innovator biologic, but they must notify a prescriber within five days.